Jose Teodoro

Dr. Jose Teodoro

Department of Biochemistry, Goodman Cancer Research Institute, McGill University, Montreal, Canada
orcid

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 August 2001 in Science
Verified
Journal Article
Closed access
PDF file
LDLaxminarayana R. Devireddy
Laxminarayana R. Devireddy
Jose TeodoroJose Teodoro
Jose Teodoro
FRFabien A. Richard
Fabien A. Richard
MGMichael R. Green
Michael R. Green
Many hematopoietic cells undergo apoptosis when deprived of specific cytokines, and this process requires de novo RNA/protein synthesis. Using DNA microarrays to analyze interleukin-3 (IL-3)–dependent murine FL5.12 pro–B cells, we found that the gene undergoing maximal transcriptional induction after cytokine withdrawal is 24p3 , which encodes a secreted lipocalin. Conditioned medium from IL-3–deprived FL5.12 cells contained 24p3 and induced apoptosis in naı̈ve FL5.12 cells even when IL-3 was present. 24p3 also induced apoptosis in a wide variety of leukocytes but not other cell types. Apoptotic sensitivity correlated with the presence of a putative 24p3 cell surface receptor. We conclude that IL-3 deprivation activates 24p3 transcription, leading to synthesis and secretion of 24p3, which induces apoptosis through an autocrine pathway.

29 April 2009 in PLOS ONE
Verified
Journal Article
Open access
PDF file
RCRegina Cencic
Regina Cencic
MCMarilyn Carrier
Marilyn Carrier
GGGabriela Galicia-Vázquez
Gabriela Galicia-Vázquez
MBMarie-Eve Bordeleau
Marie-Eve Bordeleau
RSRami Sukarieh
Rami Sukarieh
JPJerry Pelletier
Jerry Pelletier
Flavaglines are a family of natural products from the genus Aglaia that exhibit anti-cancer activity in vitro and in vivo and inhibit translation initiation. They have been shown to modulate the activity of eIF4A, the DEAD-box RNA helicase subunit of the eukaryotic initiation factor (eIF) 4F complex, a complex that stimulates ribosome recruitment during translation initiation. One flavagline, silvestrol, is capable of modulating chemosensitivity in a mechanism-based mouse model. Among a number of flavagline family members tested herein, we find that silvestrol is the more potent translation inhibitor among these. We find that silvestrol impairs the ribosome recruitment step of translation initiation by affecting the composition of the eukaryotic initiation factor (eIF) 4F complex. We show that silvestrol exhibits significant anticancer activity in human breast and prostate cancer xenograft models, and that this is associated with increased apoptosis, decreased proliferation, and inhibition of angiogenesis. We demonstrate that targeting translation by silvestrol results in preferential inhibition of weakly initiating mRNAs. Our results indicate that silvestrol is a potent anti-cancer compound in vivo that exerts its activity by affecting survival pathways as well as angiogenesis. We propose that silvestrol mediates its effects by preferentially inhibiting translation of malignancy-related mRNAs. Silvestrol appears to be well tolerated in animals.

23 June 2007 in Journal of Molecular Medicine
Verified
Journal Article
Closed access
PDF file
Jose TeodoroJose Teodoro
Jose Teodoro
SESara K. Evans
Sara K. Evans
MGMichael R. Green
Michael R. Green

18 August 2006 in Science
Verified
Journal Article
Closed access
PDF file
Jose TeodoroJose Teodoro
Jose Teodoro
APAlbert E. Parker
Albert E. Parker
XZXiaochun Zhu
Xiaochun Zhu
MGMichael R. Green
Michael R. Green
Recent evidence suggests that antiangiogenic therapy is sensitive to p53 status in tumors, implicating a role for p53 in the regulation of angiogenesis. Here we show that p53 transcriptionally activates the α(II) collagen prolyl-4-hydroxylase [α(II)PH] gene, resulting in the extracellular release of antiangiogenic fragments of collagen type 4 and 18. Conditioned media from cells ectopically expressing either p53 or α(II)PH selectively inhibited growth of primary human endothelial cells. When expressed intracellularly or exogenously delivered, α(II)PH significantly inhibited tumor growth in mice. Our results reveal a genetic and biochemical linkage between the p53 tumor suppressor pathway and the synthesis of antiangiogenic collagen fragments.

31 August 2009 in Cancer Research
Verified
Journal Article
Closed access
PDF file
CWChristian Welch
Christian Welch
MSManas K. Santra
Manas K. Santra
WEWissal El-Assaad
Wissal El-Assaad
XZXiaochun Zhu
Xiaochun Zhu
WHWade E. Huber
Wade E. Huber
MGMichael R. Green
Michael R. Green
The Bcl-2 family of proteins consists of both antiapoptotic and proapoptotic factors, which share sequence homology within conserved regions known as Bcl-2 homology domains. Interactions between Bcl-2 family members, as well as with other proteins, regulate apoptosis through control of mitochondrial membrane permeability and release of cytochrome c. Here we identify a novel regulator of apoptosis that lacks Bcl-2 homology domains but acts by binding Bcl-2 and modulating its antiapoptotic activity. To identify regulators of apoptosis, we performed expression profiling in human primary fibroblasts treated with tumor necrosis factor-α (TNF-α), a potent inflammatory cytokine that can regulate apoptosis and functions, at least in part, by inducing expression of specific genes through NF-κB. We found that the gene undergoing maximal transcriptional induction following TNF-α treatment was G0-G1 switch gene 2 (G0S2), the activation of which also required NF-κB. We show that G0S2 encodes a mitochondrial protein that specifically interacts with Bcl-2 and promotes apoptosis by preventing the formation of protective Bcl-2/Bax heterodimers. We further show that ectopic expression of G0S2 induces apoptosis in diverse human cancer cell lines in which endogenous G0S2 is normally epigenetically silenced. Our results reveal a novel proapoptotic factor that is induced by TNF-α through NF-κB and that interacts with and antagonizes Bcl-2. [Cancer Res 2009;69(17):6782–9]

1 November 2009 in Cancer Cell
Verified
Journal Article
Closed access
EPEmmanuel Petroulakis
Emmanuel Petroulakis
APArmen Parsyan
Armen Parsyan
RDRyan J.O. Dowling
Ryan J.O. Dowling
OBOlivier Le Bacquer
Olivier Le Bacquer
YMYvan MARTINEAU
Yvan MARTINEAU
NSNahum Sonenberg
Nahum Sonenberg